Jubilant to work with Endo Pharmaceuticals on Drug Development

Collaboration to provide Endo Pharmaceuticals with new drug candidates in Oncology

June 11, 2009, Noida-India

Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of Oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development. 

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization. 

Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed. 

Endo Pharmaceuticals, is a specialty pharmaceutical company engaged in R&D, sales and marketing of branded and generic medicines in pain management, urology, endocrinology and oncology 

Commenting on the Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: 

"We are pleased to announce this collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo’s expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant’s mission to be India’s largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care."

Dr. Ivan Gergel M.D., Executive Vice President, Research & Development of Endo Pharmaceuticals said: "We are excited about this opportunity with Jubilant. We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients."

_{Notes to the Editors}

About Jubilant Biosys  

Jubilant Biosys Ltd. (www.jubilantbiosys.com) is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modelling, crystallography and information technology to support collaborations with global pharma companies in USA , Europe and Japan. For more information, visit www.jubilantbiosys.com

About Jubilant Organosys  

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India . The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services ,generic dosage forms and Health Care. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world. For more information, please visit www.jubl.com

---ENDS---

For more information on release, contact: